Main Menu

Carlos A. Zarate, Jr., MD. is Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the NIH National Institute of Mental Health (NIMH) and Clinical Professor of Psychiatry and Behavioral Sciences at The George Washington University. Dr. Zarate formed the Experimental Therapeutics and Pathophysiology Branch at the NIMH in 2009. Dr. Zarate has had a prolific career researching the treatment of mood and anxiety disorders, most recently licensing an invention that led to the development of the first FDA-approved drug for treatment-resistant depression (Spravato®). Dr. Zarate’s Branch conducts proof-of-concept studies utilizing novel compounds and biomarkers (magnetoencephalography [MEG] and polysomnography [PSG], positron emission tomography [PET], functional magnetic resonance imaging [fMRI] and magnetic resonance spectroscopy [MRS]) to identify potentially relevant drug targets and biosignatures of treatment response. He is a member of the National Academy of Medicine and was the NIH Distinguished Lecturer for the 16th Annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer hosted by the NIH. His talk was on developing novel medications for treatment resistant depression and bipolar disorder. If you are interested in working with Dr. Zarate, you can find the technologies he has available for licensing or collaboration on the NIH Technology Transfer website.